Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Misato Hashi"'
Autor:
Daiju Oba, Yoichi Matsubara, Yasumi Nakashima, Tetsuya Niihori, Yoko Aoki, Shin Ichi Inoue, Shigeo Kure, Mitsuji Moriya, Sachiko Miyagawa-Tomita, Misato Hashi, Hiroshi Ohnishi
Publikováno v:
Human molecular genetics. 24(25)
Activation of the RAS pathway has been implicated in oncogenesis and developmental disorders called RASopathies. Germline mutations in BRAF have been identified in 50-75% of patients with cardio-facio-cutaneous (CFC) syndrome, which is characterized
Autor:
Misato Hashizume
Publikováno v:
Inflammation and Regeneration, Vol 40, Iss 1, Pp 1-8 (2020)
Abstract In this review article, it is highlighted the implications of pleiotropic functions of interleukin-6 (IL-6) for one of the therapeutic options targeting for COVID-19. Moreover, it is discussed how real-world data and trials with IL-6 signali
Externí odkaz:
https://doaj.org/article/129ea98e3e404292a4584dcde5db4e94
Autor:
Mitsuji Moriya, Shin-ichi Inoue, Sachiko Miyagawa Tomita, Yasumi Nakashima, Daiju Oba, Tetsuya Niihori, Misato Hashi, Hiroshi Ohnishi, Shigeo Kure, Yoichi Matsubara, Yoko Aoki
Publikováno v:
Human Molecular Genetics; 12/20/2015, Vol. 24 Issue 25, p7349-7360, 12p
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-9 (2018)
Abstract Background Clinical trials have shown combinations of anti–tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption th
Externí odkaz:
https://doaj.org/article/7dea4c52ebb74545b01449c222eeade7
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152341 (2016)
Externí odkaz:
https://doaj.org/article/7f1a5f346c224d8d8ce8e3afecc9fdcd
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0145468 (2015)
To explore the baseline predictors of clinical effectiveness after tocilizumab or infliximab treatment in biologic-naïve rheumatoid arthritis patients.Consecutive biologic-naïve patients with rheumatoid arthritis initiating infliximab (n = 57) or t
Externí odkaz:
https://doaj.org/article/b445184b372942dea03d6d264e4de5f4